Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.44 |
| ▸ | LOX | P28300 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19969290 | 0.98 | LMNA (0.50) | LMNAAOC3LOXMEN1NR1I2 | |
| SCHEMBL9970103 | 0.86 | AOC3 (0.44) | LMNAAOC3LOXMEN1NR1I2 | |
| SCHEMBL9970102 | 0.84 | AOC3 (0.45) | LMNAAOC3LOXMEN1NR1I2 | |
| SCHEMBL14646864 | 0.79 | LMNA (0.56) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL28052195 | 0.73 | CHUK (0.41) | LMNAMEN1NR1I2CHRM2CYP3A4 | |
| SCHEMBL16021958 | 0.70 | LMNA (0.56) | LMNAAOC3LOXMEN1KMT2A | |
| SCHEMBL12948943 | 0.70 | LMNA (0.65) | LMNAAOC3MEN1KMT2AKDM4E | |
| SCHEMBL14682728 | 0.70 | LMNA (0.65) | LMNAAOC3MEN1KMT2AKDM4E | |
| SCHEMBL28214210 | 0.70 | ESR1 (0.40) | CHUKDAPK3JAK2ROCK2PRKCG | |
| SCHEMBL24319905 | 0.70 | KDM4E (0.44) | LMNAMEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330049-A1 | COMPOSITIONS AND METHODS OF USE OF GAMMA-KETOALDHEYDE SCAVENGERS FOR TREATING, PREVENTING OR IMPROVING FIBROSIS OF THE LIVER | MTI BIOTECH, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230181494-A1 | COMPOSITIONS AND METHODS OF USE OF GAMMA-KETOALDEHYDE SCAVENGERS FOR TREATING, PREVENTING OR IMPROVING NONALCOHOLIC FATTY LIVER DISEASE (NAFLD), NASH, ALD OR CONDITIONS RELATED TO THE LIVER | MTI BIOTECH, INC. | 2023-06-15 | — | — | US | disclosed |
| US-10975033-B2 | Methods for treating inflammation and hypertension with γ-ketoaldehyde skavengers | VANDERBILT UNIVERSITY (US) | 2021-04-13 | — | — | US | disclosed |
| US-10688109-B1 | Methods of preventing platelet activation | VANDERBILT UNIVERSITY (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190314302-A1 | USE OF 2-HYDROXYBENZYLAMINE IN THE TREATMENT AND PREVENTION OF PULMONARY HYPERTENSION | VANDERBILT UNIVERSITY | 2019-10-17 | — | — | US | disclosed |
| US-20190247375-A1 | Prevention And Treatment Of Atrial Fibrillation/Flutter With Gamma-Ketoaldehyde Scavengers | VANDERBILT UNIVERSITY | 2019-08-15 | — | — | US | disclosed |
| US-20190240170-A1 | Use of Scavengers of Reactive Gamma-Ketoaldehydes to Extend Cell Lifespan and Healthspan | VANDERBILT UNIVERSITY | 2019-08-08 | — | — | US | disclosed |
| US-20190099387-A1 | COMPOSITIONS AND METHODS OF USE OF GAMMA-KETOALDHEYDE SCAVENGERS FOR TREATING, PREVENTING OR IMPROVING FIBROSIS OF THE LIVER | MTI BIOTECH | 2019-04-04 | — | — | US | disclosed |
| WO-2019050967-A1 | COMPOSITIONS AND METHODS OF USE OF GAMMA-KETOALDHEYDE SCAVENGERS FOR TREATING, PREVENTING OR IMPROVING FIBROSIS OF THE LIVER | METABOLIC TECHNOLOGIES, INC. (US) | 2019-03-14 | — | — | WO | disclosed |
| US-10166248-B1 | Methods of preventing platelet activation | VANDERBILT UNIVERSITY (US) | 2019-01-01 | — | — | US | disclosed |
| WO-2018093936-A1 | USE OF 2-HYDROXYBENZYLAMINE IN THE TREATMENT AND PREVENTION OF PULMONARY HYPERTENSION | VANDERBILT UNIVERSITY (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018048932-A1 | COMPOSITIONS AND METHODS OF USE OF GAMMA-KETOALDEHYDE SCAVENGERS FOR TREATING, PREVENTING OR IMPROVING NONALCOHOLIC FATTY LIVER DISEASE (NAFLD), NASH, ALD OR CONDITIONS RELATED TO THE LIVER | METABOLIC TECHNOLOGIES, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975033-B2 | Methods for treating inflammation and hypertension with γ-ketoaldehyde skavengers | NFKBIA, AKR1B1, TNF | LMNA 1000/4885AOC3 729/4885LOX 162/4885 |
| US-10166248-B1 | Methods of preventing platelet activation | PFKP, PLG, PRKG1 | LMNA 433/4885AOC3 3168/4885LOX 57/4885 |
| US-20190314302-A1 | USE OF 2-HYDROXYBENZYLAMINE IN THE TREATMENT AND PREVENTION OF PULMONARY HYPERTENSION | SIRT3, SIRT2, GLS | LMNA 1073/4885AOC3 3538/4885LOX 2090/4885 |
| US-10688109-B1 | Methods of preventing platelet activation | PFKP, PLG, PRKG1 | LMNA 433/4885AOC3 3168/4885LOX 57/4885 |
| US-20230181494-A1 | COMPOSITIONS AND METHODS OF USE OF GAMMA-KETOALDEHYDE SCAVENGERS FOR TREATING, PREVENTING OR IMPROVING NONALCOHOLIC FATTY LIVER DISEASE (NAFLD), NASH, ALD OR CONDITIONS RELATED TO THE LIVER | CPT1A, AKR7A2, FABP1 | LMNA 703/4885AOC3 480/4885LOX 145/4885 |
| US-20190247375-A1 | Prevention And Treatment Of Atrial Fibrillation/Flutter With Gamma-Ketoaldehyde Scavengers | KCNH1, AKR7A2, GLO1 | LMNA 837/4885AOC3 860/4885LOX 464/4885 |
| US-20190099387-A1 | COMPOSITIONS AND METHODS OF USE OF GAMMA-KETOALDHEYDE SCAVENGERS FOR TREATING, PREVENTING OR IMPROVING FIBROSIS OF THE LIVER | GGT1, GGH, AKR7A2 | LMNA 1628/4885AOC3 615/4885LOX 139/4885 |
| US-20190240170-A1 | Use of Scavengers of Reactive Gamma-Ketoaldehydes to Extend Cell Lifespan and Healthspan | HOGA1, GLB1, HAGH | LMNA 946/4885AOC3 1716/4885LOX 759/4885 |
| US-20230330049-A1 | COMPOSITIONS AND METHODS OF USE OF GAMMA-KETOALDHEYDE SCAVENGERS FOR TREATING, PREVENTING OR IMPROVING FIBROSIS OF THE LIVER | GGT1, GGH, AKR7A2 | LMNA 1628/4885AOC3 615/4885LOX 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.